Лабораторные биомаркеры поражения сердца при системной склеродермии. Часть 1
https://doi.org/10.14412/1996-7012-2026-2-7-12
Аннотация
Поражение сердца – одно из тяжелых проявлений системной склеродермии (ССД), которое варьируется от субклинических форм до опасных для жизни состояний, характеризуется плохим прогнозом и высокой смертностью. Кардиопатия при ССД может быть первичной и вторичной, связанной с сопутствующими заболеваниями. Поэтому важную роль играет своевременная диагностика первичного поражения сердца, в частности определение сывороточных биомаркеров.
В обзоре рассмотрены варианты лабораторных биомаркеров для выявления первичного поражения сердца при ССД, их вклад в раннюю диагностику и прогнозирование течения заболевания.
При поддержке: Статья подготовлена в рамках фундаментальной научной темы РК 125020501434-1.
Об авторах
Л. А. Гарзанова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
Людмила Александровна Гарзанова
Москва, 115522, Москва, Каширское шоссе, 34А
Л. П. Ананьева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
Москва, 115522, Москва, Каширское шоссе, 34А
О. А. Конева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
Москва, 115522, Москва, Каширское шоссе, 34А
О. Б. Овсянникова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
Москва, 115522, Москва, Каширское шоссе, 34А
Литература
1. Volkmann ER, Andreasson K, Smith V. Systemic sclerosis. Lancet. 2023 Jan 28; 401(10373):304-318. doi: 10.1016/S0140-6736(22)01692-0.
2. Bournia VK, Tountas C, Protogerou AD, et al. Update on assessment and management of primary cardiac involvement in systemic sclerosis. J Scleroderma Relat Disord. 2018 Feb;3(1):53-65. doi: 10.1177/2397198317747441.
3. Moore DF, Steen VD. Overall mortality. J Scleroderma Relat Disord. 2021 Feb;6(1): 3-10. doi: 10.1177/2397198320924873.
4. Guedon AF, Carrat F, Mouthon L, et al. Heart and systemic sclerosis-findings from a national cohort study. Rheumatology (Oxford). 2024 Dec 1;63(12):3380-3389. doi: 10.1093/rheumatology/kead599.
5. Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017 Nov; 76(11):1897-1905. doi: 10.1136/annrheumdis-2017-211448.
6. Pinter T, Faludi R, Magyari B, et al. Mechanism of coronary flow reserve reduction in systemic sclerosis: insight from intracoronary pressure wire studies. Rheumatology (Oxford). 2011 Apr;50(4):781-8. doi: 10.1093/rheumatology/keq402.
7. Kahan A, Coghlan G, McLaughlin V. Cardiac complications of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3: iii45-8. doi: 10.1093/rheumatology/kep110.
8. Bruni C, Ross L. Cardiac involvement in systemic sclerosis: Getting to the heart of the matter. Best Pract Res Clin Rheumatol. 2021 Sep;35(3):101668. doi: 10.1016/j.berh.2021.101668.
9. Bruni C, Buch MH, Furst DE, et al. Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. J Scleroderma Relat Disord. 2022 Feb; 7(1):24-32. doi: 10.1177/23971983211053246.
10. Wermuth PJ, Piera-Velazquez S, Rosenbloom J, Jimenez SA. Existing and novel biomarkers for precision medicine in systemic sclerosis. Nat Rev Rheumatol. 2018 Jul; 14(7):421-432. doi: 10.1038/s41584-018-0021-9.
11. Leclair V, D'Aoust J, Gyger G, et al. Canadian Inflammatory Myopathy Study Group. Autoantibody profiles delineate distinct subsets of scleromyositis. Rheumatology (Oxford). 2022 Mar;61(3):1148-1157. doi: 10.1093/rheumatology/keab492.
12. Ананьева ЛП, Александрова ЕН Аутоантитела при системной склеродермии: спектр, клинические ассоциации и прогностическое значение. Научно-практическая ревматология. 2016;54(1):86-99.
13. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov; 72(11):1747-55. doi: 10.1136/annrheumdis-2013-204424.
14. Cavazzana I, Vojinovic T, Airo' P, et al. Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. Clin Rev Allergy Immunol. 2023 Jun;64(3):412-430. doi: 10.1007/s12016-022-08946-w.
15. Mahler M, Hudson M, Bentow C, et al. Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. Autoimmun Rev. 2020 Aug;19(8):102583. doi: 10.1016/j.autrev.2020.102583.
16. Nihtyanova SI, Sari A, Harvey JC, et al. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis. Arthritis Rheumatol. 2020 Mar;72(3):465-476. doi: 10.1002/art.41153.
17. Aggarwal R, Lucas M, Fertig N, et al. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum. 2009 Apr;60(4): 1112-8. doi: 10.1002/art.24409.
18. Tormey VJ, Bunn CC, Denton CP, Black CM. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford). 2001 Oct;40(10):1157-62. doi: 10.1093/rheumatology/40.10.1157.
19. Keppeke GD, Satoh M, Kayser C, et al. A cell-based assay for detection of anti-fibrillarin autoantibodies with performance equivalent to immunoprecipitation. Front Immunol. 2022 Sep;13:1011110. doi: 10.3389/fimmu.2022.1011110.
20. Kaji K, Fertig N, Medsger TA Jr, et al. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res (Hoboken). 2014 Apr;66(4):575-84. doi: 10.1002/acr.22163.
21. Pauling JD, Salazar G, Hui Lu, et al. Presence of anti-eukaryotic initiation factor- 2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis. Rheumatology (Oxford). 2018 Apr;57(4):712-717. doi: 10.1093/rheumatology/kex458.
22. Di Pietro L, Chiccoli F, Salvati L, et al. Anti-RuvBL1/2 Autoantibodies Detection in a Patient with Overlap Systemic Sclerosis and Polymyositis. Antibodies (Basel). 2023 Feb; 12(1):13. doi: 10.3390/antib12010013.
23. Caforio AL, Tona F, Bottaro S, et al. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity. 2008 Feb;41(1):35-45. doi: 10.1080/08916930701619235.
24. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013 Sep;34(33):2636-48, 2648a- 2648d. doi: 10.1093/eurheartj/eht210.
25. Caforio AL, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J. 2007 Jun;28(11):1326-33. doi: 10.1093/eurheartj/ehm076.
26. Peretto G, Sala S, De Luca G, et al. Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias. JACC Clin Electrophysiol. 2020 Oct;6(10):1221-1234. doi: 10.1016/j.jacep.2020.05.013.
27. Blagova O, Varionchik N, Zaidenov V, et al. Anti-heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID-19. Eur J Immunol. 2021 Apr;51(4):893-902. doi: 10.1002/eji.202048930.
28. Caforio ALP, De Luca G, Baritussio A, et al. Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates. Diagnotics (Basel). 2021 Nov;11(11):2165. doi: 10.3390/diagnostics11112165.
29. Lewis RA, Durrington C, Condliffe R, Kiely DG. BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing? Eur Respir Rev. 2020 May;29(156): 200009. doi: 10.1183/16000617.0009-2020.
30. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A. 2000 Apr;97(8):4239-44. doi: 10.1073/pnas.070371497.
31. Thakkar V, Stevens WM, Prior D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a casecontrol study. Arthritis Res Ther. 2012 Jun; 14(3):R143. doi: 10.1186/ar3876.
32. Ross L, Moxey J, Nikpour M. Are troponin and B-type natriuretic peptides useful biomarkers for the diagnosis of systemic sclerosis heart involvement? A systematic literature review. Semin Arthritis Rheum. 2021 Feb; 51(1):299-309. doi: 10.1016/j.semarthrit.2020.10.016.
33. Bosello S, De Luca G, Berardi G, et al. Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. Eur J Intern Med. 2019 Feb;60:46-53. doi: 10.1016/j.ejim.2018.10.013.
34. Ciurzynski M, Bienias P, Irzyk K, et al. Serum endothelin-1 and NT-proBNP, but not ADMA, endoglin and TIMP-1 levels, reflect impaired right ventricular function in patients with systemic sclerosis. Clin Rheumatol. 2014 Jan;33(1):83-9. doi: 10.1007/s10067-013-2354-8.
35. Chighizola C, Meroni PL, Schreiber BE, et al. Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patients. Clin Exp Rheumatol. 2012 Mar-Apr; 30(2 Suppl 71):S81-5.
36. Allanore Y, Komocsi A, Vettori S, et al. N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis. Int J Cardiol. 2016 Nov;223:385-389. doi: 10.1016/j.ijcard.2016.08.246.
37. Dumitru RB, Bissell LA, Erhayiem B, et al. Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers. RMD Open. 2021 Oct;7(3):e001689. doi: 10.1136/rmdopen-2021-001689.
38. Bissell LA, Anderson M, Burgess M, et al. Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. Rheumatology (Oxford). 2017 Jun;56(6):912- 921. doi: 10.1093/rheumatology/kew488.
39. Alehagen U, Dahlström U, Lindahl TL. Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail. 2009 Apr; 11(4):354-60. doi: 10.1093/eurjhf/hfp024.
40. Patel PC, Ayers CR, Murphy SA, et al. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail. 2009 Mar;2(2):98-104. doi: 10.1161/CIRCHEARTFAILURE.108.807271.
41. Filler G, Bökenkamp A, Hofmann W, et al. Cystatin C as a marker of GFR – history, indications, and future research. Clin Biochem. 2005 Jan;38(1):1-8. doi: 10.1016/j.clinbiochem.2004.09.025.
42. Krusche M, Osei-Davies R, Becker I, et al. Renal Function in Patients With Systemic Sclerosis: Do We Estimate It Correctly? J Clin Rheumatol. 2022 Mar;28(2):e642-e646. doi: 10.1097/RHU.0000000000001791.
43. Siegert E, March C, Otten L, et al. Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis. Nutrition. 2018 Nov;55-56:51-55. doi: 10.1016/j.nut.2018.03.046.
44. Akkus O, Bozkurt A, Arslantas D, et al. Is cystatin C an evaluative marker for right heart functions in systemic sclerosis? Int J Cardiol. 2016 Oct;221:478-83. doi: 10.1016/j.ijcard.2016.07.093.
45. Jha M, Wang M, Steele R, et al. NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: Findings from the Canadian Scleroderma Research Group. J Scleroderma Relat Disord. 2022 Feb;7(1):62-70. doi: 10.1177/23971983211040608.
46. Barsotti S, Stagnaro C, d'Ascanio A, et al. High sensitivity troponin might be a marker of subclinical scleroderma heart involvement: a preliminary study. J Scleroderma Relat Disord. 2017 July;2(3):183-187. doi: 10.5301/jsrd.5000244
Рецензия
Для цитирования:
Гарзанова ЛА, Ананьева ЛП, Конева ОА, Овсянникова ОБ. Лабораторные биомаркеры поражения сердца при системной склеродермии. Часть 1. Современная ревматология. 2026;20(2):7-12. https://doi.org/10.14412/1996-7012-2026-2-7-12
For citation:
Garzanova LA, Ananyeva LP, Koneva OA, Ovsyannikova OB. Laboratory biomarkers of cardiac involvement in systemic sclerosis. Part 1. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2026;20(2):7-12. (In Russ.) https://doi.org/10.14412/1996-7012-2026-2-7-12
Просмотров:
415
JATS XML
Послать статью по эл. почте 
